[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633381":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":52,"collaborators":23,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":23,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":23,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":38,"whyStopped":23,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Jade Biosciences, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"JADE101 Groups 1 and 2","EXPERIMENTAL","Subcutaneous (SC) injection of JADE101",[13],"Drug: JADE101",{"label":15,"type":10,"description":11,"interventionNames":16},"JADE101 Groups 3 and 4",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","JADE101","JADE101 is supplied as sterile solution to be administered by SC injection",[9,15],null,[25],{"name":26,"affiliation":27,"role":28},"Li Li, MD","Jade Biosciences","STUDY_DIRECTOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":23,"email":34},"Han","CONTACT","+1-888-228-7425","study.losangeles@parexel.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Parexel Early Phase Clinical Unit (EPCU)","RECRUITING","Glendale","California","91206","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-118.25508,34.14251,{"lat":48,"lon":47},[51],{"name":31,"role":32,"phone":33,"phoneExt":23,"email":34},{"type":53,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100633381","phase-1-a-single-dose-phase-1-study-of-jade101-in-healthy-japanese-and-chinese-participants-100633381",false,"NCT07525947","A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants","A Phase 1, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Japanese and Chinese Participants.","Inclusion Criteria:\n\n1. Healthy male or female participants 18-55 years of age, inclusive\n2. First-generation Japanese or Chinese participants born in Japan\u002FChina\n3. A body weight between 40-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg\u002Fm2 (all inclusive) at screening\n4. Willing and able to comply with the study site stay, scheduled visits, and study procedures\n5. Willing and able to comply with contraceptive and lifestyle requirements from admission through the end of the study\n\nExclusion Criteria:\n\n1. Harmful alcohol use\n2. Smoking\u002Fvaping or heavy tobacco use within 2 years prior to screening\n3. Known history of abuse of illicit drugs\n4. Nursing, lactating or pregnant, or who have plans to become pregnant during the study\n5. Known history of clinically significant disease\n6. Known history of immunodeficiency disorder\n7. History of clinically significant allergic reactions or hypersensitivity",true,"ALL","18 Years","55 Years",{"count":66,"type":67},40,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.",[73],"Healthy Volunteers (HV)",[20],"2026-06-02",{"date":77,"type":78},"2026-06-04","ACTUAL",{"date":80,"type":78},"2026-05-01",{"date":82,"type":67},"2027-05",{"name":5,"class":6},1]